This finding has been related to AD where to PP2A activity is reduced by up to 50% in AD brains (Voronkov et al., 2011; Martin et al., 2013a), observations pointing towards the potential of targeting PP2A for therapy in tauopathies, although this relation has yet to be explored in PD. Here, PTPA is linked to Parkinson disease.